1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Conatus Pharmaceuticals Inc. - Product Pipeline Review - 2013

Conatus Pharmaceuticals Inc. - Product Pipeline Review - 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 25 pages

Conatus Pharmaceuticals Inc. - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Conatus Pharmaceuticals Inc. - Product Pipeline Review - 2013” provides data on the Conatus Pharmaceuticals Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Conatus Pharmaceuticals Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Conatus Pharmaceuticals Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Conatus Pharmaceuticals Inc. - Brief Conatus Pharmaceuticals Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Conatus Pharmaceuticals Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Conatus Pharmaceuticals Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Conatus Pharmaceuticals Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Conatus Pharmaceuticals Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Conatus Pharmaceuticals Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Conatus Pharmaceuticals Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Conatus Pharmaceuticals Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Conatus Pharmaceuticals Inc. and identify potential opportunities in those areas.

Table Of Contents

Conatus Pharmaceuticals Inc. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Conatus Pharmaceuticals Inc. Snapshot 4
Conatus Pharmaceuticals Inc. Overview 4
Key Information 4
Key Facts 4
Conatus Pharmaceuticals Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Conatus Pharmaceuticals Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Conatus Pharmaceuticals Inc. - Pipeline Products Glance 9
Conatus Pharmaceuticals Inc. Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Conatus Pharmaceuticals Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Conatus Pharmaceuticals Inc. - Drug Profiles 12
emricasan 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
IDN-13389 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
IDN-8050 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Conatus Pharmaceuticals Inc. - Pipeline Analysis 15
Conatus Pharmaceuticals Inc. - Pipeline Products by Therapeutic Class 15
Conatus Pharmaceuticals Inc. - Pipeline Products By Target 17
Conatus Pharmaceuticals Inc. - Pipeline Products by Route of Administration 18
Conatus Pharmaceuticals Inc. - Pipeline Products By Mechanism of Action 19
Conatus Pharmaceuticals Inc. - Recent Pipeline Updates 21
Conatus Pharmaceuticals Inc. - Discontinued Pipeline Products 22
Discontinued Pipeline Product Profiles 22
CTS-1027 22
Conatus Pharmaceuticals Inc. - Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

List of Tables

Conatus Pharmaceuticals Inc., Key Information 4
Conatus Pharmaceuticals Inc., Key Facts 4
Conatus Pharmaceuticals Inc. - Pipeline by Indication, 2013 6
Conatus Pharmaceuticals Inc. - Pipeline by Stage of Development, 2013 7
Conatus Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2013 8
Conatus Pharmaceuticals Inc. - Phase II, 2013 9
Conatus Pharmaceuticals Inc. - Phase I, 2013 10
Conatus Pharmaceuticals Inc. - Preclinical, 2013 11
Conatus Pharmaceuticals Inc. - Pipeline By Therapeutic Class, 2013 16
Conatus Pharmaceuticals Inc. - Pipeline By Target, 2013 17
Conatus Pharmaceuticals Inc. - Pipeline By Route of Administration, 2013 18
Conatus Pharmaceuticals Inc. - Pipeline Products By Mechanism of Action, 2013 20
Conatus Pharmaceuticals Inc. - Recent Pipeline Updates, 2013 21
Conatus Pharmaceuticals Inc. - Discontinued Pipeline Products, 2013 22

List of Figures

Conatus Pharmaceuticals Inc. - Pipeline by Indication, 2013 6
Conatus Pharmaceuticals Inc. - Pipeline by Stage of Development, 2013 7
Conatus Pharmaceuticals Inc. - Monotherapy Products in Pipeline, 2013 8
Conatus Pharmaceuticals Inc. - Pipeline By Therapeutic Class, 2013 15
Conatus Pharmaceuticals Inc. - Pipeline Products By Mechanism of Action, 2013 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Nuclear Factor Erythroid 2 Related ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.